COVID-19: лечение и профилактика
"Oral antiviral candidate Paxlovid™ reduces COVID-19 risks by 89 percent
Paxlovid™, Pfizer’s investigational oral antiviral candidate, displayed
an 89 percent reduction in COVID-19 risks in Phase II/III study.
Pfizer has announced its investigational novel COVID-19 oral antiviral
candidate, Paxlovid™, significantly reduced hospitalisation and death,
based on an interim analysis of the Phase II/III EPIC-HR randomised,
double-blind study of non-hospitalised adult patients with COVID-19, who
are at high risk of progressing to severe illness."
https://www.europeanpharmaceuticalre...by-89-percent/
https://www.pfizer.com/news/press-re...ment-candidat
https://www.bmj.com/content/375/bmj.n2713
"The UK government has purchased 250 000 courses of paxlovid, which is a combination of PF-07321332 and ritonavir*
Commenting on the announcement, England’s health and social care
secretary, Sajid Javid, said, “If approved, this could be another
significant weapon in our armoury to fight the virus alongside our
vaccines and other treatments, including molnupiravir, which the UK was
the first country in the world to approve this week.”
* Справка:
PF-07321332 https://clinicaltrials.gov/ct2/show/NCT04756531
Ritonavir was patented in 1989 and came into medical use in 1996. It is on the World Health Organization's List of Essential Medicines.
Ritonavir was one of the first protease inhibitors developed, but is no
longer used as an anti-HIV drug due to its side effects. However, it is
given at very low doses (too low for anti-HIV effects) to ‘boost’ the
level of other protease inhibitors. https://www.aidsmap.com/about-hiv/ar...heet/ritonavir